Literature DB >> 9158757

Penicillin-binding proteins 2x and 2b as primary PBP targets in Streptococcus pneumoniae.

J Krauss1, M van der Linden, T Grebe, R Hakenbeck.   

Abstract

Different penicillin-binding proteins PBPs are affected in cefotaxime-resistant laboratory mutants compared to piperacillin-resistant mutants. PBP2x acts as the primary PBP target in cefotaxime-resistant mutants, whereas PBP2b is the primary target in piperacillin-resistant mutants. Depending on the mutations in PBP2x, it functions as a resistance determinant for cefotaxime only, or for penicillins as well. Mutations in PBP2x of laboratory mutants are found exclusively in the penicillin-binding domain that contains three homology boxes common to all penicillin-interacting enzymes. Most mutations relevant for resistance occur close to the SXN or the KT/SG box, or at the C-terminal end of the penicillin-binding domain, similar to mutations described in PBP2b of laboratory mutants. Amino acid alterations occur at similar sites also in PBP2x of beta-lactam-resistant clinical isolates and most of these proteins also contain changes in the SXXK box with the active site serine, suggesting that these alterations may be critical for resistance development in clinical isolates.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9158757     DOI: 10.1089/mdr.1996.2.183

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  16 in total

Review 1.  Molecular detection of antimicrobial resistance.

Authors:  A C Fluit; M R Visser; F J Schmitz
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  All detectable high-molecular-mass penicillin-binding proteins are modified in a high-level beta-lactam-resistant clinical isolate of Streptococcus mitis.

Authors:  A Amoroso; D Demares; M Mollerach; G Gutkind; J Coyette
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

3.  Diversity of substitutions within or adjacent to conserved amino acid motifs of penicillin-binding protein 2X in cephalosporin-resistant Streptococcus pneumoniae isolates.

Authors:  Y Asahi; Y Takeuchi; K Ubukata
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

4.  Amino acid mutations essential to production of an altered PBP 2X conferring high-level beta-lactam resistance in a clinical isolate of Streptococcus pneumoniae.

Authors:  Anthony M Smith; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

5.  Safety and robustness aspects analysis of Lactobacillus delbrueckii ssp. bulgaricus LDB-C1 based on the genome analysis and biological tests.

Authors:  Yuxuan Guan; Yanhua Cui; Xiaojun Qu; Kai Jing
Journal:  Arch Microbiol       Date:  2021-05-22       Impact factor: 2.552

Review 6.  Multimodular penicillin-binding proteins: an enigmatic family of orthologs and paralogs.

Authors:  C Goffin; J M Ghuysen
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

7.  A novel resistance mechanism against beta-lactams in Streptococcus pneumoniae involves CpoA, a putative glycosyltransferase.

Authors:  T Grebe; J Paik; R Hakenbeck
Journal:  J Bacteriol       Date:  1997-05       Impact factor: 3.490

Review 8.  Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.

Authors:  James E Frampton
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

9.  A mutation in the D,D-carboxypeptidase penicillin-binding protein 3 of Streptococcus pneumoniae contributes to cefotaxime resistance of the laboratory mutant C604.

Authors:  J Krauss; R Hakenbeck
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

10.  Biochemical characterization of Streptococcus pneumoniae penicillin-binding protein 2b and its implication in beta-lactam resistance.

Authors:  Estelle Pagliero; Laurent Chesnel; Julie Hopkins; Jacques Croizé; Otto Dideberg; Thierry Vernet; Anne Marie Di Guilmi
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.